AstraZeneca Return-to-Growth Journey (Sponsored Event)
Tell a Friend About This EventTell a Friend

When: Wednesday, July 6th
Noon to 1:30 PM
Where: Hilton
750 Kearny Street
San Francisco, California  94108
United States
Contact: Ameeta

Online registration is closed.
« Go to Upcoming Event List  


Return-to-Growth Journey


AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and
commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory,
inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide. For more information, please visit:


AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has
the potential to transform patients' lives and the Company's future. With at least 6 new medicines to be launched
between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to
advance New Oncology as one of AstraZeneca's six Growth Platforms focused on lung, ovarian, breast and blood
cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate
the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms -- immuno-oncology, the genetic drivers of cancer and resistance,
DNA damage repair and antibody drug conjugates --and by championing the development of personalized
combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of


About our Speaker 


Mitchell Chan

Director of Investor Relations, AstraZeneca, North America
Mitchell Chan is responsible for managing AstraZeneca's Investor Relations in North America. In this capacity he is
responsible for Oncology and North American operations. Before AstraZeneca, Mitchell worked at Genentech/Roche,
where he held roles in Mergers &Acquisitions, Commercial Finance, and Global Product Development Finance. He
graduated with a BSc in Biochemistry, an MSc in Molecular Biophysics, and an MBA from the University of Toronto.




Wednesday, July 6th 



Noon to 1:30 PM 



Financial District 

750 Kearny Street

San Francisco, 94108




235 Montgomery Street, Suite 725 | San Francisco, CA 94104 | P: 415.814.7900 | E:

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.